Paratek Pharmaceuticals (PRTK) on Tuesday said it had received the FDA's expedited Fast Track designation for its NUZYRA (omadacycline) antibiotic treating...
...
...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 75 Park Plaza Boston, Massachusetts 02116-3934 |
| Phone | +1.617.807.6600 |
| Number of Employees | 104 |
| Recent SEC Filing | 06/09/2022 8-K |
| Chief Executive Officer & Director | Evan Loh |
| President & Chief Commercial Officer | Adam Woodrow |
| VP, Chief Financial & Accounting Officer | Sarah Higgins |
| Vice President-Information Technology | Raj Padmanabhan |
| Price Open | $1.92 |
| Previous Close | $1.93 |
| 52 Week Range | $1.60 - 7.27 |
| Market Capitalization | $106.8 M |
| Shares Outstanding | 54.5 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.16 |
| Beta vs. S&P 500 | N/A |
| Revenue | $17.1 M |
| Net Profit Margin | -42.38% |
| Return on Equity | 49.74% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
